People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calidi Biotherapeutics, Inc. | — | Biotechnology | Series A | $15.2M | $30.2M | 2023 |
Anthony F. Santidrian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anthony F. Santidrian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Jackson | 1 | 4 |
| George Ng | 1 | 4 |
| Alan R. Stewart | 1 | 4 |
| James A. Schoeneck | 1 | 3 |
| Boris Minev | 1 | 1 |
| Stephen Thesing | 1 | 1 |
| Tony Kalajian | 1 | 1 |
| Amish F. Patel | 1 | 1 |
| David F. Sans | 1 | 1 |
| Wendy Pizarro | 1 | 1 |
| Scott F. Leftwich | 1 | 1 |
| George R. Ng | 1 | 1 |
| Scott R. Leftwich | 1 | 1 |
| Allan Camaisa | 1 | 1 |
| David A. LaPre | 1 | 1 |
| Heehyoung F. Lee | 1 | 1 |
| James F. Schoeneck | 1 | 1 |
| Alfonso F. Zulueta | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.